[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Transcranial Current Stimulation (tTIS) Targeting Ventral Posterolateral Nucleus for Pain Treatment","EXPERIMENTAL","tTIS (10Hz envelope field, current intensity 2-4mA) targeted at ventral posterolateral nucleus (contralateral to the pain side) for 5 consecutive days (20 minutes\u002F day)",[13],"Device: 10Hz tTIS (2-4mA) Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","10Hz tTIS (2-4mA) Intervention","tTIS (10Hz envelope field, current intensity 2-4mA)",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jun GUO, Dr","CONTACT","(86)13991269132","guojun_81@163.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Tangdu Hospital","RECRUITING","Xi'an","Shaanxi","710038","China","CN",{"type":37,"coordinates":38},"Point",[39,40],108.92861,34.25833,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Jun Guo, MD","Associate Professor","100621952","efficacy-and-safety-of-transcranial-temporal-interference-stimulation-ttis-for-neuropathic-pain-in-neuromyelitis-optica-spectrum-disorder-nmosd-100621952",false,"NCT07377305","Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)","A Single-center, Prospective, Single-arm Clinical Study: Evaluation of the Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)","Inclusion Criteria:\n\n* Patients diagnosed with NMOSD in accordance with the criteria of the International Panel for Neuromyelitis Optica Diagnosis (IPND).\n* Patients were complicated with neuropathic pain, with a DN4 score ≥ 4.\n* NRS score for pain ≥ 4 points, and neuropathic pain has persisted for more than 3 months.\n* Patients receiving biological therapy and\u002For prednisone at a stable dose, with no adjustment of the treatment plan within 30 days before enrollment.\n* Patients who have not adjusted any combination of standard analgesic drugs (including antiepileptic drugs, antidepressants, and opioid drugs) within 30 days before enrollment.\n* Patients or their family members who have signed a written informed consent form.\n\nExclusion Criteria:\n\n* Subjects participating in other clinical studies.\n* Subjects who have used investigational drugs for pain control within 30 days before enrollment.\n* Subjects with a concurrent diagnosis of peripheral neuropathy.\n* Subjects with concurrent active central nervous system diseases.\n* Subjects with cognitive or mental disorders.\n* Subjects who are pregnant, lactating, or planning to become pregnant during the study period.\n* Subjects with severe diseases related to the heart, liver, kidneys, or hematopoietic system.\n* Subjects with implanted devices in the body (such as cardiac pacemakers, nerve stimulators, etc.).\n* Subjects with a history of transcutaneous electrical nerve stimulation (TENS) allergy, latex allergy, or previous intolerance.\n* Subjects with contraindications to MRI examination.\n* Subjects with head skin lesions.\n* Other medical conditions or situations that the researcher deems may affect the achievement of the study objectives.","ALL","18 Years","75 Years",{"count":59,"type":60},12,"ESTIMATED","INTERVENTIONAL",[63],"NA","This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD) complicated by neuropathic pain in China.",[66],"NMO Spectrum Disorder","2026-01-22",{"date":69,"type":70},"2026-01-29","ACTUAL",{"date":72,"type":70},"2025-12-08",{"date":74,"type":60},"2026-09-30",{"name":5,"class":6},1]